Multiple myeloma: prognosis and standard treatment.
Oken
M M
MM
Virginia Piper Cancer Institute, Minneapolis, Minnesota 55407, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis
D000970:Antineoplastic Agents; D015415:Biomarkers; D005938:Glucocorticoids; D007372:Interferons; D008558:Melphalan